Want to see NKTX full AI Analyst Report?
NKTX Stock Chart & Stats
$3.47
-$0.05(-2.07%)
At close: 4:00 PM EST
$3.47
-$0.05(-2.07%)
Day’s Range― - ―
52-Week Range$1.70 - $3.72
Previous CloseN/A
Volume369.36K
Average Volume (3M)692.94K
Market Cap
$212.49M
Enterprise Value$236.52M
Total Cash (Recent Filing)$230.43M
Total Debt (Recent Filing)$75.00M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 06, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding71,545,360
10 Day Avg. Volume874,449
30 Day Avg. Volume692,943
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-101.08
Enterprise Value/Ebitda-2.61
Forecast
1Y Price Target
$11.80Price Target Upside240.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.44
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Allogeneic NK Cell PlatformNkarta’s off-the-shelf allogeneic NK cell approach is a durable business-model advantage vs autologous therapies: it can scale manufacturing, lower per-patient complexity, and address multiple cancer indications (hematologic and solid tumors), supporting a scalable commercial pathway if clinical success materializes.
Moderate LeverageBalance sheet leverage is modest for a clinical-stage biotech, implying limited interest burden and greater financial flexibility. This structural strength helps preserve runway and supports continued R&D investment without the immediate constraints faced by highly leveraged peers.
Strengthened GovernanceRecent shareholder approvals (director elections, auditor ratification, annual say-on-pay) indicate clearer governance and enhanced shareholder oversight. Stronger governance reduces execution and oversight risk, improving investor confidence in strategic decisions and compensation alignment over the medium term.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow represents a structural funding requirement: the company must access external capital to continue programs. Persistent cash burn increases dilution risk and constrains strategic optionality, making execution dependent on future financings or partnerships.
Pre-revenue ProfileAs a pre-commercial biotech with no product revenue, Nkarta lacks internal cash generation to fund operations. Long-term success hinges on clinical outcomes, regulatory progress, or partnerships, creating binary upside and limited near-term visibility into sustainable earnings or cash flow.
Declining Shareholder EquitySteady erosion of shareholders' equity reflects capital consumption and cumulative losses. This reduces the balance-sheet cushion, raises the probability of future dilution or financing needs, and limits the company’s flexibility to scale programs without external funding.
Nkarta News
NKTX FAQ
What was Nkarta, Inc.’s price range in the past 12 months?
Nkarta, Inc. lowest stock price was $1.70 and its highest was $3.72 in the past 12 months.
What is Nkarta, Inc.’s market cap?
Nkarta, Inc.’s market cap is $212.49M.
When is Nkarta, Inc.’s upcoming earnings report date?
Nkarta, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 25 days.
How were Nkarta, Inc.’s earnings last quarter?
Nkarta, Inc. released its earnings results on May 12, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.354 by -$0.016.
Is Nkarta, Inc. overvalued?
According to Wall Street analysts Nkarta, Inc.’s price is currently Undervalued.
Does Nkarta, Inc. pay dividends?
Nkarta, Inc. does not currently pay dividends.
What is Nkarta, Inc.’s EPS estimate?
Nkarta, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Nkarta, Inc. have?
Nkarta, Inc. has 71,545,360 shares outstanding.
What happened to Nkarta, Inc.’s price movement after its last earnings report?
Nkarta, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.354. Following the earnings report the stock price went down -6.707%.
Which hedge fund is a major shareholder of Nkarta, Inc.?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.80 (240.06% Upside)
$11.80 (240.06% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 846.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.00%
12-Months-Change
Fundamentals
Return on Equity
-30.90%
Trailing 12-Months
Asset Growth
-20.94%
Trailing 12-Months
Company Description
Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$11.80
▲(240.06% Upside)
Technical Analysis
Ownership Overview
20.64% Insiders
7.77% Mutual Funds
2.32% Other Institutional Investors
62.25% Public Companies and
Individual Investors